Wave Life Sciences (WVE) Company Report

Wave Life Sciences is advancing its RNA medicines pipeline, with key programs in RNA editing and siRNA, and anticipates a data-rich period in Q4 2025 and 2026.
The WVE-007 (inhibin E) program for obesity demonstrated dose-dependent reductions in activin E levels in clinical data, with a 75% reduction at 240 mg and an 85% reduction at 400 mg.
Upcoming catalysts for WVE-007 include three-month data on the 240 mg cohort in Q4 2025 and six-month data on the 240 mg cohort and three-month data on the 400 mg cohort in Q1 2026, focusing on fat loss and body composition.
The WVE-006 RNA editing program for alpha-1 antitrypsin deficiency (AATD) showed potent and durable editing, correcting patients to the MZ phenotype with over 20 micromolar of total protein and nearly 11 micromolar of M protein at the lowest single dose.
Wave plans to initiate clinical trials for WVE-008 (PNPLA3), an RNA editing program for liver disease, in 2026, targeting a large patient population.

Nov 20, 2025, 9:00 AM

Transcript

Wave Life Sciences Discusses Progress on Obesity and AATD Programs

WVE

New Projects/Investments

Wave Life Sciences provided an update on its WVE-007 (inhibin E) program for obesity, reporting dose-dependent reductions in activin E levels, with the 240 mg dose achieving a 75% reduction at day 29 and the 400 mg dose an 85% reduction.
The company anticipates a Q4 2025 update on three-month data for the 240 mg WVE-007 cohort, including body composition and metabolic biomarkers, with six-month data for this cohort and three-month data for the 400 mg cohort expected in Q1 2026.
For its WVE-006 RNA editing program for Alpha-1 antitrypsin deficiency (AATD), previous data showed potent and durable editing, with the lowest single dose correcting a patient to over 20 micromolar of protein. An update on the 400 mg dose cohort is expected, focusing on durability and M protein editing efficiency.
Wave Life Sciences plans to advance WVE-008 (PNPLA3), a new RNA editing program targeting liver disease, into the clinic in 2026, aiming for a large patient population.

Nov 20, 2025, 9:00 AM

Transcript

Wave Life Sciences Details Progress on Obesity and Genetic Disease Programs

WVE

New Projects/Investments

Guidance Update

Wave Life Sciences (WVE) is focused on developing a fully integrated RNA medicines platform, with key programs in RNA editing and siRNA.
The company's WVE-007 program for obesity demonstrated dose-dependent, statistically significant reductions in activin E levels in humans, with the 240 mg dose achieving a 75% reduction and the 400 mg dose an 85% reduction at day 29, both still declining.
Upcoming data for WVE-007 includes three-month data for the 240 mg cohort in Q4 2025, assessing activin E nadir, metabolic biomarkers, and body composition, followed by six-month data for 240 mg and three-month data for 400 mg in Q1 2026.
Wave Life Sciences also reported potent, durable, and specific RNA editing with WVE-006 for alpha-1 antitrypsin deficiency (AATD), correcting patients to near-normal M protein levels, with further data from the 400 mg dose cohort expected.
The company plans to advance WVE-008, an RNA editing program for PNPLA3 (liver disease), into the clinic in 2026, targeting a substantial patient population.

Nov 20, 2025, 9:00 AM

Transcript

Wave Life Sciences Ltd. Provides Corporate Presentation and Pipeline Updates

WVE

New Projects/Investments

Product Launch

Wave Life Sciences Ltd. is well-capitalized with a cash runway into Q2 2027.
The company's diversified RNA medicines pipeline includes WVE-007 for obesity, with clinical data updates expected starting in Q4 2025.
Upcoming regulatory milestones include an IND application for WVE-003 (Huntington's Disease) in 2H 2025, a CTA filing for WVE-008 (liver disease) in 2026, and an NDA filing for WVE-N531 (Duchenne muscular dystrophy) in 2026.
Additional clinical data for WVE-006 (Alpha-1 antitrypsin deficiency) is expected in Q1 2026 and throughout 2026.

Nov 17, 2025, 12:30 PM

8-K

Wave Life Sciences Provides Update on RNA Editing and Obesity Programs

WVE

New Projects/Investments

Wave Life Sciences is advancing WVE-006, an alpha-1 antitrypsin RNA editing program, which is the first of its kind in the clinic. It has demonstrated greater than 50% protein editing and the ability to mount an over 20 micromolar response during acute exacerbations, with the company emphasizing its GalNAc delivery and subcutaneous administration as key differentiators.
The company's WVE-007 program for obesity, targeting inhibin E, has shown single-dose weight loss similar to semaglutide with all fat loss and no lean muscle mass loss in preclinical models. Human data indicates up to 85% reduction in activin E protein at the 400mg dose, with further dose escalation approved.
WVE-007 is being developed as a potential once or twice a year maintenance therapy for obesity, with the first three-month data expected this quarter and six-month data in Q1 to assess fat loss and durability. The company plans to independently run Phase 2 studies, noting a clear registrational path for obesity therapies.

Nov 11, 2025, 3:00 PM

Transcript

Wave Life Sciences Announces Positive WVE-007 Clinical Trial Data for Obesity and New Pipeline Candidate

WVE

New Projects/Investments

Wave Life Sciences Ltd. announced positive target engagement data from its INLIGHT clinical trial evaluating WVE-007 for obesity on October 29, 2025.
The trial demonstrated dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007, exceeding levels that led to weight loss in preclinical models.
Activin E reductions in the lowest dose cohort were sustained through 6 months, supporting potential once or twice yearly dosing, and WVE-007 has been generally safe and well tolerated to date.
The company anticipates multiple clinical data updates from the INLIGHT trial, including body composition and body weight, starting in 4Q 2025, with further readouts expected in 1Q 2026 and 2Q 2026.
Wave Life Sciences also announced WVE-008 as its PNPLA3 RNA editing clinical candidate for liver disease, with a Clinical Trial Application (CTA) submission anticipated in 2026.

Oct 29, 2025, 9:22 PM

8-K

Wave Life Sciences Provides Clinical Updates on WVE-006 and WVE-007, Introduces WVE-008

WVE

New Projects/Investments

Wave Life Sciences provided updates on its RNA editing and siRNA programs, highlighting progress in WVE-006 for AATD and WVE-007 for obesity.
For WVE-006 (AATD), the RESTORATION2 trial demonstrated restoration of the MZ phenotype, achieving AAT levels up to 13 micromolar and 64% wild-type MAAT, with effects persisting for up to two months. Data from the 400 mg dose cohort is anticipated in Q1 2026, and 600 mg data in 2026.
WVE-007 (obesity) showed highly significant dose-dependent activin E reductions in the INLIGHT clinical trial, with an 85% reduction for the 400 mg dose at day 29, surpassing preclinical targets for fat loss. This durability supports once or twice a year dosing, with potential for fat loss comparable to semaglutide by six months.
Upcoming data updates for WVE-007 include three-month follow-up from the 240 mg cohort later this quarter, six-month follow-up from the 240 mg cohort and three-month follow-up from the 400 mg cohort in Q1 2026, and 600 mg data throughout 2026.
The company also introduced WVE-008, a new RNA editing candidate for PNPLA3 liver disease, with a CTA filing projected for 2026.

Oct 29, 2025, 2:00 PM

Transcript

WaveLife and Aeronaut Discuss ADAR RNA Editing Progress for Alpha-1 Antitrypsin Deficiency

WVE

New Projects/Investments

WaveLife (WVE) presented clinical data for its lead ADAR RNA editing program targeting Alpha-1 Antitrypsin Deficiency (AATD), demonstrating MZ-like protein total levels of up to 13 micromolar and a shift from 0% Z protein to 44% M protein after a single dose, and 65% M protein after multiple doses in the lowest dose cohort.
WaveLife's (WVE) drug also showed the ability to mount a 20 micromolar response to an acute phase event, with editing sustained for over two months on a single dose, and anticipates further data from the 400 mg cohort in Q1.
Aeronaut, a private company, shared preclinical data for its AATD program, highlighting up to 39 micromolar MAAT and 63 micromolar total AAT in mouse models, and durability with a half-life extending over 30 days in monkeys, with a CTA filing expected by the end of this year.
The panel expressed strong confidence in ADAR as a therapeutic enzyme, noting that RNA editing technology is evolving rapidly and is expected to achieve broad applicability much faster than previous siRNA technologies.

Oct 21, 2025, 5:00 PM

Transcript

Wave Life Sciences, ProQR, and Arana Provide Updates on ADAR RNA Editing Programs

WVE

New Projects/Investments

Product Launch

Wave Life Sciences (WVE) reported clinical data for its lead alpha-1 antitrypsin deficiency (AATD) program, WVE-006, demonstrating MZ-like total protein levels of 12-13 micromolar and a significant increase in M protein from 0% to 44% after a single dose in the lowest cohort. Further data from the 400 mg cohort is anticipated in Q1.
ProQR announced clearance to initiate a Phase 1 trial for AX-810, its lead program targeting NTCP for cholestatic diseases, making it the second ADAR editing target to enter human studies. The trial will assess safety and tolerability, and measure target engagement through increases in serum bile acids, aiming for a twofold increase.
Arana is preparing for a CTA filing by the end of this year for its AATD program, following preclinical data showing high M-AAT levels (up to 39 micromolar) and total AAT (up to 63 micromolar) in mouse models, and durability with a half-life exceeding 30 days in monkeys.

Oct 21, 2025, 5:00 PM

Transcript

Weave Bio Secures $20M Series A Funding

WVE

New Projects/Investments

Hiring

Weave Bio announced it secured $20 million in Series A funding, bringing its total capital raised to $36 million.
The funding round was led by USVP, with participation from Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital.
This capital will be used to accelerate product development for its AI-native Weave Platform, expand its commercial team, and facilitate expansion into global markets beyond the U.S. FDA.
The Weave Platform is an AI-native solution built to support regulatory workflows across the entire therapeutic lifecycle for pharmaceutical companies, biotech firms, CROs, and regulatory consultants.

Oct 16, 2025, 12:00 PM

Press Release

Earnings Transcripts

Quarterly earnings call transcripts for Wave Life Sciences.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Paul B. Bolno say about margins?What are Wave Life Sciences's strategic priorities?How is Wave Life Sciences positioned vs competitors?How did Wave Life Sciences do last quarter?

Let Fintool AI Agent track Wave Life Sciences's earnings for you

Get instant analysis when filings drop